Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Frontiers in Physiology|December 14, 2018
GDF15 and Growth ControlPaul J Emmerson, Kevin L Duffin, Sudhakar Chintharlapalli, et al.
Current Topics in Medicinal Chemistry|June 23, 2007
Melanocortin-4 receptor agonists for the treatment of obesityPaul J Emmerson, Matthew J Fisher, Liang Zeng Yan, et al.
ACS Pharmacology & Translational Science|March 29, 2020
Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases?Kyle W Sloop, Daniel A Briere, Paul J Emmerson, et al.
British Journal of Pharmacology|February 3, 2018
The current state of GPCR-based drug discovery to treat metabolic diseaseKyle W Sloop, Paul J Emmerson, Michael A Statnick, et al.
European Journal of Pharmacology|June 24, 2004
Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonistsPaul J Emmerson, Jamie H McKinzie, Peggy L Surface, et al.
Plos One|June 23, 2017
Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouseRichard G Peterson, Charles Van Jackson, Karen M Zimmerman, et al.
Plos One|June 23, 2017
Correlation of disease severity with body weight and high fat diet in the FATZO/Pco mouseBrian A Droz, Bria L Sneed, Charles V Jackson, et al.
Molecular Metabolism|July 18, 2025
Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weightClaire H Feetham, Minrong Ai, Isabella Culotta, et al.
European Journal of Pharmacology|December 9, 2003
Na+-dependent high affinity binding of [3H]LY515300, a 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid receptor inverse agonistMichael A Statnick, Todd M Suter, Susan L Gackenheimer, et al.
Plos One|October 17, 2022
The hypothalamic RFamide, QRFP, increases feeding and locomotor activity: The role of Gpr103 and orexin receptorsChris Cook, Nicolas Nunn, Amy A Worth, et al.
Pageof 3